Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of aficamten in healthy Chinese participants: a randomized, double-blind, placebo-controlled, phase 1 study

Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of aficamten in healthy Chinese participants: a randomized, double-blind, placebo-controlled, phase 1 study

Objectives: Aficamten is a selective, small-molecule allosteric inhibitor of cardiac sarcomere being developed as a chronic oral treatment for patients with symptomatic obstructive hypertrophic cardiomyopathy. This was the first-in-Chinese study aiming to investigate the safety, tolerability, pharma...

Full description

Bibliographic Details
Main Authors: Xue Zhao, Hongzhong Liu, Wei Tian, Ligang Fang, Mengyang Yu, Xiaofei Wu, Aijing Liu, Ruijie Wan, Li Li, Jinghui Luo, Yuqiong Li, Bo Liu, Yu He, Xiaowen Chen, Yuan Li, Donghong Xu, Hongyun Wang, Xiaohong Han
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Pharmacology
Subjects:
aficamten
Chinese participants
safety
pharmacokinetics
pharmacodynamics
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1227470/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1227470/full

Similar Items